Table 2.
Significantly enriched KEGG pathways of DEGs
| Mutation | Term | Count | P-value |
|---|---|---|---|
| CSMD3 | hsa04142: Lysosome | 8 | 0.002 |
| hsa04010: MAPK signaling pathway | 10 | 0.015 | |
| hsa05230: Central carbon metabolism in cancer | 5 | 0.016 | |
| hsa04610: Complement and coagulation cascades | 5 | 0.021 | |
| hsa01130: Biosynthesis of antibiotics | 8 | 0.044 | |
| EPB41L3 | hsa01200: Carbon metabolism | 8 | 0.003 |
| hsa01130: Biosynthesis of antibiotics | 11 | 0.004 | |
| hsa01100: Metabolic pathways | 33 | 0.010 | |
| hsa00020: Citrate cycle (TCA cycle) | 4 | 0.015 | |
| hsa04730: Long-term depression | 5 | 0.020 | |
| hsa04130: SNARE interactions in vesicular transport | 4 | 0.021 | |
| hsa04720: Long-term potentiation | 5 | 0.028 | |
| hsa03022: Basal transcription factors | 4 | 0.044 | |
| hsa04726: Serotonergic synapse | 6 | 0.045 | |
| PCLO | hsa04810: Regulation of actin cytoskeleton | 11 | <0.001 |
| hsa04151: PI3K-Akt signaling pathway | 12 | 0.005 | |
| hsa04510: Focal adhesion | 9 | 0.005 | |
| hsa04512: ECM-receptor interaction | 6 | 0.005 | |
| hsa03320: PPAR signaling pathway | 5 | 0.011 | |
| hsa05205: Proteoglycans in cancer | 8 | 0.016 | |
| hsa05160: Hepatitis C | 6 | 0.031 | |
| hsa05231: Choline metabolism in cancer | 5 | 0.044 | |
| RYR1 | hsa00500: Starch and sucrose metabolism | 3 | 0.019 |
| hsa04010: MAPK signaling pathway | 6 | 0.023 | |
| hsa04960: Aldosterone-regulated sodium reabsorption | 3 | 0.026 | |
| hsa00280: Valine, leucine and isoleucine degradation | 3 | 0.037 | |
| hsa01130: Biosynthesis of antibiotics | 5 | 0.048 |
Abbreviations: MAPK, mitogen activated kinase-like protein; TCA, tricarboxylic acid; SNARE, small NF90 (ILF3) associated RNA E; PI3K-Akt:phosphoinositide-3-kinase/serine threonine kinase; ECM, extracellular matrix; PPAR, peroxisome proliferators-activated receptors.